Akaal Pharma Strengthens Global IP Position with Japanese Patent Grant

by

Greater Shepparton, Victoria, Australia — 29 May 2026 Akaal Pharma Pty Ltd (Akaal Pharma) has strengthened its global intellectual property portfolio with the grant of a patent in Japan, protecting its lead clinical-stage Sphingosine-1-Phosphate receptor subtype-1 (S1P1) agonists, TAKP-119 and OAKP-11. The patent, titled “S1P Receptor Modulators” (Japan Patent No. 7850669), provides broad protection across … Read more

Akaal Pharma Pty Ltd Announces Positive Phase-2 Results for S1P1 Agonist in the Treatment of Atopic Dermatitis and Associated Pruritus

by

Greater Shepparton, Victoria, Australia – 10 June 2025: Akaal Pharma Pty Ltd (Akaal Pharma), a biopharmaceutical company focused on novel therapies for inflammatory and autoimmune skin disorders, today announced positive top-line results from its Phase 2 clinical trial. The multicenter, randomized, double-blind, placebo-controlled study evaluated its selective Sphingosine-1-Phosphate-receptor subtype-1 (S1P1) agonist, Takp-119, in patients with … Read more